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In our medicinal organic chemistry research lab, I am performing a ninhydrin-based enzyme inhibition assay, previously developed in our lab, to discover novel antibiotics to combat antibiotic resistance that poses an imminent public
health crisis. These drugs target the bacterial enzyme N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE), a crucial enzyme to bacterial survival due to its involvement in the biosynthetic pathway of lysine, an amino acid essential
to protein synthesis and mDAP, which is essential for bacterial cell wall construction. This pathway is exclusive to bacteria and is not found in mammalian cells, thus inhibition of this enzyme should be selectively toxic to bacteria. The
assay enables testing of potential new inhibitors of DapE, done by spectrophotometric analysis of the products of the in vitro enzyme assay, quantitatively analyzing the amount of enzyme substrate converted to product. The goal is to
evaluate several newly discovered inhibitor series involving indoline sulfonamides, tetrazoles, and N-aryl sulfonamides. Studying analogs of these compounds will greatly aid our understanding of the enzyme dynamics involved in the
inhibition process. This information will broaden our understanding of the enzyme’s catalytic machinery to significantly aid in our future endeavors of drug synthesis and drug discovery for the optimization of new inhibitors.

Background

Methodology

Although the world currently faces a major battle against the
global COVID-19 pandemic, a longer-term ongoing fight continues
against an increase in antibiotic resistant bacteria, underscoring
the urgent need to discover antibiotics with a new mechanism of
action.1 The Becker research group is addressing this increase in
mortality and morbidity in order to advance our fight against
antibiotic resistance. Our medicinal chemistry research has
revealed the possibility of an entirely new class of antibiotics,
which targets a previously-unexplored biochemical pathway,
Utilizing inhibition of the enzymatic activity
of N-succinyl-L,L-diaminopimelic acid
desuccinylase, or DapE (inset). 2 This enzyme
is part of a crucial biosynthetic pathway that
produces the amino acid lysine and mDAP,
both essential to protein synthesis and
bacterial peptidoglycan cell wall
construction, respectively. Therefore,
inhibition of DapE enzymatic activity is very
attractive because its inhibition should be
selectively lethal to bacteria, while safe for
humans, as we receive lysine from our diet,
and we do not express the DapE enzyme.

In order to demonstrate inhibition of DapE to test potential antibiotic efficacy, the biochemical
assay developed in our research group3 is utilized. This consists of the incubation of the active
DapE enzyme, a modified substrate, N-methylsuccinyl diaminopimelic acid (N-Me-SDAP), HEPES
buffer, and the inhibitor. In addition, the potential inhibitors are tested at various concentrations at
30℃ for 10 minutes, then the reaction is quenched by heating for 1 minute to deactivate the
enzyme. Then, ninhydrin is added, which reacts with the primary amine of the now-cleaved
product, converting the solution to a shade of purple. The absorbance at 570 nm is then measured
in a spectrophotometer through the utilization of a well-plate reader, and different absorbance
values are obtained, which represent the amount of substrate converted to product within the
assay. After subtracting background absorbance, the inhibition for each concentration of inhibitor
is calculated. After running the assay in triplicate, using 100% enzymatic activity, 0% enzymatic
activity, and glutamic acid controls, the IC50 of each potential inhibitor can be accurately obtained.3
Within medicinal chemistry and drug discovery, the IC50 refers to half the maximum inhibitory
concentration, and it is utilized to compare the effect that potential drugs have on specific
biological pathways or processes. It is one of the most common ways to report inhibitory effects of
small molecule drug candidates. Now, with this inhibition data, the synthesized compounds may be
compared with previously identified DapE inhibitors, such as the thiol-containing ACE inhibitor
captopril, to determine their efficacy as potential new antibiotics. In addition, these data facilitate
an understanding of the structure-activity relationships (SAR) between our synthesized compounds
and the enzyme and enable us to iteratively improve our analogs.

Objectives

Lead Molecules as DapE Inhibitors
Figure 1 contains the lead structure from each inhibitor series to demonstrate the wide variety of inhibitors
being tested in our critical assay. Some lead molecules are in their beginning stages of synthesis, while the
Becker group has just published advanced inhibitors based on the indolines 1 and 2.4

To work in collaboration with graduate students as well as
undergraduate students within Dr. Becker’s research group who are
synthesizing compounds that require testing in the assay to obtain
their inhibitory potency against DapE.
Through the utilization of the computational suite, the Molecular
Operating Environment (MOE), and a High Throughput Screen (HiTS),
we discovered several potential new inhibitor series for DapE, which
include indoline sulfonamides4, tetrazoles, and N-aryl sulfonamides.
Our group has also designed cyclobutanones as DapE inhibitors.5

After hypothesizing that these molecules would inhibit DapE, analogs
of the original hits were either previously synthesized or continue to
be synthesized, and then, each of these compounds must be assessed
in the assay to obtain inhibition data.
Once the inhibition data is obtained, the molecular interactions
between DapE’s structure and the potential inhibitors may be
analyzed to provide greater understanding of the enzyme dynamics
involved in the inhibition process. This greater understanding will
significantly aid in future endeavors of drug synthesis and drug
discovery for the optimization of new inhibitors.

Figure 1. Lead molecules as DapE inhibitors

Results and Conclusions
Inhibition data for a series of indolines has recently published by our group.4 We have obtained
preliminary inhibition data for series 3 and 4 inhibitors, as well as for cyclobutanones, and this data will
be published in due course. Furthermore, after performing these reactions and obtaining DapE inhibition
data, we will co-crystallize the drug candidates in collaboration with Argonne National Laboratories and
obtain high-resolution co-crystal structures of the inhibitors with the DapE enzyme to elucidate the
binding mode of the inhibitors as well as the distinct enzyme conformations6 with the different
compound moieties bound to the active sites. With this information, we will be able to advance our
understanding of the enzyme-drug interactions through an improved knowledge of the structure activity
relationship (SAR) between the different classes of inhibitors with the enzyme, which will in turn
enhance our effort toward the discovery of new antibiotics.

Continued Work
In addition, updates and improvements have been
made for streamlining our assay to enable faster
throughput and more accurate results. We are now
utilizing a thermal cycler, an instrument that
automatically regulates the temperature of the sample
and the incubation time for each of those temperatures,
all possible through programming. With the reduction of
error, every IC50 value calculated utilizing the thermal
cycler will be that much more accurate. This will greatly
impact every single project in our research lab.
Additionally, it is imperative to note our ongoing work to
broaden the scope of our research to combat growing
antibiotic resistance. Therefore, in the future, we will be
moving to set up the assay with the DapE enzyme from
different bacterial species to confirm broad spectrum
antibiotic activity. We are working in collaboration with
CSGID (Center for Structural Genomics of Infectious
Diseases) at Northwestern, as well as Argonne National
Laboratories, to expand the validation of DapE as a target
for different types of bacterial infections.
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